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Summary
Ifosfamide and doxorubicin are the most active agents in the
treatment of sarcomas and are characterized by a marked
dose-response relationship. The objective of this study was to
determine the maximum tolerated dose (MTD) of both agents
in combination under granulocyte-macrophage colony-stimu-
lating factor (GM-CSF) cover.
Patients and methods: Thirty-three patients with untreated
sarcomas (soft tissue: n - 20; gynecological: n - 11; bone: n -
2) were treated with ifosfamide 12 g/m2 by continuous i.v.
infusion over five days and doxorubicin with dose escalation
from 50 mg/m2 i.v. bolus divided on two days, then to 60 mg/m2
bolus divided on three days. Ifosfamide was reduced to 10 g/m2
and doxorubicin was further escalated up to 90 mg/m2.
GM-CSF (5 ug/kg/day subcutaneously) was started 24 hours
after chemotherapy and continued for 10 days.
Results: The MTD was reached with the combination of
ifosfamide at 12 g/m2 and doxorubicin at 60 mg/m2. But with
ifosfamide 10 g/m2 and doxorubicin 90 mg/m2 the MTD was
not obtained. While severe leukopenia and granulopenia were
observed at all-dose levels, severe anemia was more frequently
related to the highest dose of ifosfamide. Severe thrombopenia
and mucositis were more commonly observed at the highest
dose of doxorubicin. Ifosfamide 10 g/m2 and doxorubicin 90
mg/m2 induced WHO grade 4 leukopenia in 58%, grade 3-4
thrombopenia in 42%, and anemia in 31% of cycles. Mucositis
was minor in 50% of cycles. The overall response rate among
31 evaluable patients was 55% (95 confidence interval (CI):
36%-73%), with four (13%) complete responders and 13 (42%)
partial responders. Response rates based on soft-tissue sarco-
mas or gynecological sarcomas alone were similar. Ten patients
could be treated by elective surgery and/or radiotherapy. The
total group of patients reached a median survival of two years,
with 25% (SE 8%) survivors after three years.
Conclusions: The dose level of ifosfamide 10 g/m2 and
doxorubicin 90 mg/m2 with supportive GM-CSF is manage-
able in a multicenter setting and should be further tested in
regular phase II trials, including patients with gynecological
and soft-tissue sarcomas. Transient toxicity with myelosup-
pression should be accepted in order to obtain a high anti-
tumor activity of this regimen and a potential improvement in
survival.
Key words: gynecological sarcomas, high-dose doxorubicin,
high-dose ifosfamide, soft tissue sarcomas
Introduction
Improvements in anti-sarcoma therapy have been long
overdue [1]. In 40%-60% of patients, curative local treat-
ment is followed by metastatic disease, which has been
managed for more than 20 years by single-agent doxo-
rubicin as the standard chemotherapeutic regimen [2, 3].
This approach yields response rates of 20%-25% and a
median survival of 12 months. The dose-response rela-
tionship is marked, with critical doses of > 60 mg/m2
[4]. Single-agent ifosfamide has been shown to be more
active than cyclophosphamide, at a response rate similar
to that of doxorubicin in previously untreated patients
[5]. Moreover, high-dose ifosfamide (> 10 g/m2) indu-
ces significant anti-tumor activity in patients pretreated
with alkylating oxazaphosphorines, which is strongly
indicative of a dose-response relationship [6, 7]. The
effect of dose on the outcome of sarcomas remained to
be tested with high-dose doxorubicin and high-dose
ifosfamide combination regimen.
Within the standard dose range, combination of doxo-
rubicin and ifosfamide has resulted in higher response
rates than either of them as a single agent. However, there
was mainly an enhanced toxicity that was not accompa-
nied by improvement in survival [2, 3, 8]. Presumably the
dose of doxorubicin in those regimens was too small to
reveal the superiority of combination therapy to single-
agent doses. When doxorubicin was increased to 75
mg/m2 in combination with a standard dose of ifosfa-
mide (5 g/m2), the response rate improved to 45%, with
10% complete remission and longer response duration
[9]. These findings, however, were not confirmed by the
preliminary results of a large randomized study [10].
So far, no results have been available on the optimal
combination of high-dose doxorubicin and high-dose
ifosfamide in previously untreated patients with advanced
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sarcoma. The availability of hematopoietic growth fac-
tors enabled us to conduct a phase I trial aimed at
denning the maximum tolerated dose (MTD) of both
agents when given in combination.
Patients and methods
The protocol was in accordance with the Declaration of Helsinki
principles and was approved by the competent ethics commission.
Inclusion criteria
Patients were required to have histologically proven advanced soft-
tissue, bone or gynecological sarcoma. They were 18-70 years old and
had a performance status ^ 2 according to the Eastern Cooperative
Oncology Group (ECOG) criteria [11]. All had normal hematological,
renal and hepatic function. Cardiac function was tested by echocar-
diography or multigated nuclear scan and had to be within the normal
range. Previous chemotherapy and CNS metastases were exclusion
criteria. A written informed consent was obtained from all patients.
chest X-ray and computerized tomography of chest and abdomen. Full
blood count was repeated twice a week during the first cycle of chemo-
therapy and once a week in the subsequent cycles. Biochemistry,
urinalysis and creatinine clearance were performed prior to each cycle.
Evaluations after every second cycle included ECG and left ventricular
ejection fraction, as well as radiological analysis of response to treat-
ment based on the state of disease defined at presentation.
Toxicity and response were evaluated according to WHO criteria
[12], except for neurotoxicity which was measured by M.D. Anderson
score [13].
Dose delivery
In order to verify the feasibility of multiple cycles, the delivered dose
intensities (mg or g/m2) for both drugs were evaluated in each cycle at
different dose levels. Cumulative dose plots [14] are available for dose
level 5, which is recommended for phase II. They show planned and
received dose intensity, cumulative intensities at various points of time,
and total dose. The cumulative dose (in mg or g/m2) is plotted against
time for each patient. The straight line represents the planned dose
intensity. The first dose is the starting point on the drug axis, sub-
sequent doses cumulated against time represent the dose intensity of
the drug.
Study design and treatment plan
In order to define the MTD of combined ifosfamide and doxorubicin,
the treatment design was to add to a fixed dose of ifosfamide escalating
doses of doxorubicin. The first-dose level consisted in ifosfamide 12 g/m2
as a continuous infusion over five days and doxorubicin 50 mg/m2 i.v.
bolus divided over two days. Planned escalation levels of doxorubicin
were 60 mg/m2 and 75 mg/m2 i.v. bolus divided over three days. At
least, three patients were included at each dose level. If one patient
developed dose-limiting toxicity (DLT), three other patients had to be
enrolled at the same dose level. The MTD was reached when two
patients developed DLT at a particular dose level. Myelosuppression
was expected and was not the only criterion for DLT.
DLT criteria were defined as : (a) neutrophil count ^0.1 x 109/l
over more than four consecutive days; (b) platelet count $25 x 109/l
over more than four consecutive days; (c) any WHO grade 3 or 4 non-
hematological toxicity [12] excluding alopecia or nausea and vomiting.
The MTD was estimated only during the first cycle of chemotherapy.
When it was reached at ifosfamide 12 g/m2 (and doxorubicin 60
mg/m2), ifosfamide was reduced to 10 g/m2 while doxorubicin was
further escalated up to 75 mg/m2 and 90 mg/m2.
Ifosfamide was administered by continuous i.v. infusion in 2 !/day
physiological saline or 5% dextrose. Mesna 2 g/m2/day was added to
the solution over six days. Subcutaneous application of granulo-
cyte macrophage colony stimulating factor (GM-CSF, molgramostim)
5 ug/kg/day was started 24 hours after the end of ifosfamide infusion
and continued for 10 days or until neutrophils had reached > 0.5 x 1O9/1.
The DLT was studied on the first cycle only, but the treatment was
continued every three weeks until progression of disease. Dose escala-
tion was not allowed within individual patients. In the subsequent
cycles, ifosfamide was reduced by 2 g/m2 in the event of fever requiring
hospitalization and i.v. antibiotics, as well as in the event of grade 3
neurological toxicity or neutropenia and thrombopenia over more than
four days. Doxorubicin was reduced by 25% in cases of grade 3 or 4
mucositis, but not down to less than 50 mg/m2. Doxorubicin had to be
stopped in case of ^ 15% decrease in left ventricular ejection fraction
(LVEF). Before each treatment cycle, a creatinine clearance >60
ml/min. or serum creatinine < 150 umol/1 was required. Prophylactic
antiemetic treatment was at the discretion of the physicians in charge.
Response and toxicity assessment
Pretreatment evaluation included full blood count, biochemistry as-
sessment, urinalysis, creatinine clearance, ECG and LVEF, as well as
Statistics
Toxicity (nadirs and WHO grades) was described for all cycles to
provide a full overview of the frequency of episodes. Statistics however
have been calculated by patients due to the correlation between each
patient values. The Jonckheere-Terpstra test [15] was used to compare
grades of toxicity and response based on dose levels. This test is
particularly powerful in comparing progressively increasing dose lev-
els. Hematological nadirs based on dose levels were compared using
the test for trend across ordered groups developed by Cuzick [16]. As
ifosfamide was reduced while doxorubicin was being escalated, the
tests were applied both for ifosfamide levels (12 mg/m2 vs. 10 mg/m2)
and for doxorubicin levels (60 vs. 75 vs. 90 mg/m2). Association
between fever/infection and dose levels was analyzed using Fisher's
exact test.
Survival was measured from the first day of treatment until death
or until the day when the patient was last seen alive. Survival was
calculated for all 33 cases. Duration of response was measured from
initiation of chemotherapy until disease progression or death. Because
some patients in remission were subjected to additional procedures like
surgery and/or radiotherapy, the duration of response should not be
attributed to chemotherapy alone and interpreted with caution Dura-
tion of survival and response was estimated using the Kaplan-Meier
method [17].
Due to the small sample size, the exact version of each test was
used wherever possible. Exact 95% confidence intervals were derived
from the binomial distribution. Analyses were carried out with Stat-
Xact [18] and STATA [19]. All /'-values are for two-sided tests.
Results
Patients
Thirty-three patients were included in the study between
January 1993 and November 1994. Two patients could
not be analyzed for DLT because of early death due to
tumor progression before completing the first treatment
cycle. Patient characteristics are listed in Table 1. Their
median age was 47 (17-69) years. Of the 31 evaluable
patients, 19 had soft-tissue sarcomas, 10 had gynecolog-
ical sarcomas, and the remaining two patients had bone
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Table 1. Patient characteristics.
Number of patients
Sex
Male
Female
Performance status
0
1
2
Sarcoma type
Soft tissue
Leiomyosarcoma
Synoviosarcoma
Liposarcoma
Neurofibrosarcoma
Other histologies3
Gynecological
Leiomyosarcoma
Mixed mesodermal
Osteosarcoma
Chondrosarcoma
Tumor location (one or more per patient)
Local recurrence
Lung
Pleura
Lymph nodes
Liver
Bone
Other location11
33
10
23
18
13
2
20
5
3
3
2
7
11
6
5
1
1
9
14
2
8
5
4
10
a
 Other histologies comprise one of each: fibrosarcoma, maligant
fibrous histiocytoma, angiosarcoma, rhabdoid sarcoma, rhabdo-myo-
sarcoma, epithelioid sacroma, unclassified.
b
 Other locations include muscle pelvis, retroperitoneum and media-
stinum.
Table 2. Dose levels.
Dose level
1
2
3
4
5
Ifosfamide
(g/m2)
12
12
10
10
10
Doxorubicin
(mg/m2)
50
60
60
75
90
Number of
patients
7
4
6
6
8
Number of
cycles
24
14
28
24
26
sarcomas (osteosarcoma and chondrosarcoma, respec-
tively). Nineteen (61%) had histological grade 3, 10
(32%) had grade 2, and two (6%) had grade 1. Local
unresectable recurrence alone was present in four pa-
tients and in association with other metastatic sites in
five additional ones. Nodal metastases were observed in
eight patients of whom four had gynecological sarco-
mas, one a chondrosarcoma and three a soft tissue sar-
coma (epithelioid, n = 1; rhabdoid, n - 1; liposarcoma,
n = 1). Patients were treated at the dose levels summar-
ized in Table 2.
Maximum tolerated dose (MTD)
DLT was assessed during the first cycles of treatment
only. Eight patients were not monitored twice a week for
hematologic toxicity, so that an accurate measurement
of the duration of myelosuppression as required in the
protocol was not possible. They had to be replaced by
fully evaluable ones, to obtain the correct number of
patients at each dose level.
At dose level 1 (ifosfamide 12 g/m2 and doxorubicin
50 mg/m2) only one out of the six fully monitored pa-
tients developed hematologic DLT in the form of gran-
ulopenia. The MTD was reached at dose level 2 (ifosfa-
mide 12 g/m2 and doxorubicin 60 mg/m2) at which
point three patients developed granulopenia that per-
sisted longer than four days, and one of them addition-
ally exhibited grade 3 neurotoxicity.
To allow further escalation of doxorubicin at subse-
quent dose levels, the total dose of ifosfamide was
reduced to 10 g/m2. No DLT was observed with doxo-
rubicin 60 mg/m2 at dose level 3. When increased to 75
mg/m2 at dose level 4, one of the five fully monitored
patients developed DLT in the form of granulopenia and
thrombopenia. At dose level 5 (ifosfamide 10 g/m2 and
doxorubicin 90 mg/m2) there was no myelosuppression
exceeding four days, but one of the eight patients devel-
oped grade 3 mucositis. Further escalation of doxorubi-
cin was beyond the scope of this study and therefore not
performed.
Toxicity (all cycles)
After the first treatment cycle during which the DLT was
determined, the 31 patients received a total of 116 treat-
ment cycles with a median of two (one to six) cycles per
patient. Additional cycles were administered in some
cases following surgery and/or radiotherapy and have
been included in the toxicity evaluation. The results are
summarized in Table 3.
As expected, myelosuppression was the main toxic
event. The median nadirs were 0.6 (0.1-7) x 109/l for
leukocytes, 0.1 (0-5) x 104/l for granulocytes, 70 (1-425)
x 104/l for thrombocytes, and 88 (35-41) g/1 for hemo-
globin. The duration of leucopenia was a median of four
days (one to eight). Treatment was complicated by fever
and proven infection in 39% and 33% of cycles, respec-
tively. Fever occurred more frequently in cycles admin-
istered at dose levels 1 and 2 (19 of 38, 51%) than at the
higher levels (26 of 78, 33%). WHO grade 3 and 4
granulopenia ensued in 70%-95% of all cycles with no
significant differences between dose levels. Cases of
grade 3 and 4 thrombopenia were evenly distributed
across dose levels (31%—58% of cycles), except for a
lower incidence at dose level 3 (7%). Severe anemia
(WHO grades 3 and 4) occurred in 25%—43% of cycles,
again with the lowest incidence at dose level 3.
Mucositis was more frequent at high doses of doxo-
rubicin. It occurred in 54% of cycles at the highest dose
level and only in 32% at the initial dose level. CNS
toxicity - observable in only six of the 116 treatment
cycles - was not a major problem owing to the schedule
of ifosfamide administration.
Microscopic hematuria was noted in seven cycles,
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Table 3. Toxicity according to dose levels (all cycles; WHO grade 0 not
reported).
Table 4. Toxicity according to dose levels (patients; WHO grade 0 not
reported).
Leucocytes (WHO grade)
I
II
III
IV
Granulocytes (WHO grade)
I
II
III
IV
Thrombocytes (WHO grade)
I
II
III
IV
Hemoglobin (WHO grade)
I
II
III
IV
Mucosa (WHO grade)
I
II
III
IV
CNS (MD Anderson score)
I
II
III
IV
Dose levelsa
I
(24)
1
4
4
14
1
1
1
14
5
2
2
5
4
5
7
3
2
5
—
-
2
_
—
-
II
(14)
-
-
-
14
-
1
-
12
3
4
2
5
1
4
3
3
-
5
_
1
1
-
1
-
Ill
(28)
2
1
5
14
2
-
2
16
2
6
2
0
7
7
6
1
5
1
_
_
1
_
—
-
IV
(24)
-
1
7
15
-
1
-
19
4
4
8
6
6
7
6
1
5
3
2
-
1
—
_
-
V
(26)
1
1
9
15
-
1
5
14
6
4
7
4
7
9
5
3
8
4
2
_
_
_
_
-
Leucocytes (WHO grade)
I
II
III
IV
Granulocytes (WHO grade)
I
II
III
IV
Thrombocytes (WHO grade)
I
II
III
IV
Hemoglobin (WHO grade)
I
II
III
IV
Mucosa (WHO grade)
I
II
III
IV
CNS (MD Anderson score)
I
II
III
IV
Dose levels"
I
(7)
_
_
1
6
_
—
_
7
2
1
0
2
1
2
1
3
1
3
—
1
_
-
II
(4)
-
_
4
-
_
4
-
_
1
3
-
_
1
3
-
3
1
-
_
1
-
Ill
(6)
_
1
_
5
_
_
_
6
-
2
2
_
-
3
1
1
3
1
_
_
1
_
_
-
IV
(6)
-
_
-
6
-
_
_
6
1
-
2
3
-
2
3
1
-
2
2
_
1
_
_
-
V
(8)
-
_
1
7
-
_
1
7
1
0
3
3
-
3
3
2
1
1
2
—
-
_
_
-
1
 In parentheses = number of cycles. a
 In parentheses = number of patients.
albeit with no clinically relevant increase in serum crea-
tinine.
Toxicity was directly attributable to GM-CSF in 15%
of cycles and consisted in fever (15%), flu-like syndrome
(8%), myalgia or erythema (12%).
Toxicity (patients)
Table 4 gives a breakdown of toxicity events by patients,
based on the highest degree experienced by each patient.
WHO grade 4 granulopenia was present in all pa-
tients but one, with no differences between dose levels.
Grade 3 and 4 thrombopenia varied across dose levels
(29%-100% of patients), with a lower incidence at levels
1 and 3 (29%-33%). There was a trend toward deeper
thrombocyte nadirs with increasing doses of doxorubi-
cin (P = 0.12). Severe anemia (grades 3 and 4) occurred
in 34%-100% of patients, with the lowest incidence at
level 3. Hemoglobin nadirs tended to be deeper as the
dose of ifosfamide was increased (P = 0.057).
Treatment was complicated by fever and proven in-
fection in 87% and 68% of patients, respectively. All
patients developed fever at the first two dose levels with
ifosfamide at 12 mg/m2, which was slightly, albeit not
significantly, less frequent with ifosfamide at 10 g/m2 (16
of 20 = 80%; P = 0.27). One patient died of septic shock
(dose level 5).
Mucositis beyond WHO grade 2 occurred in 16% of
patients. CNS toxicity was observed in only four pa-
tients and was generally mild, except in one patient who
developed grade 3 toxicity with reduced verbal output,
comprehension problems and vertigo. Reduction of
ifosfamide in the second cycle resulted in grade-1 con-
sciousness problems. One patient showed Fanconi's syn-
drome-like symptoms.
Twenty-one patients (68%) underwent regular cardiac
monitoring. None of them developed clinical heart failure
or a significantly reduced left ventricular ejection frac-
tion; however, only three patients received ^ 400 mg/m2
of doxorubicin.
In five patients (16%), side-effects and low tolerability
necessitated discontinuation of GM-CSF, which was
subsequently replaced by G-CSF, that was well toler-
ated.
Treatment was discontinued in three patients because
of toxic events: one patient had febrile granulopenia,
grade 4 thrombopenia complicated by retinal hemor-
rhage (third cycle, dose level 2), and another one had
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Figure 1 Plots of cumulative doses of (a) ifosfamide and (b) doxo-
rubicin at dose level 5. The first dose (in mg/m2) is the starting point
on the drug axis; subsequent doses are cumulated against time and
reflect the dose intensity of the drug. The straight line represents the
planned dose intensity, the dots mark the individual doses adminis-
tered. No lines for individual patients are given to facilitate visual
comparison between planned and delivered dose intensities. For both
drugs there was a tendency toward dose reduction (up to 20% for
ifosfamide and up to 17% for doxorubicin) in the subsequent cycles.
severe sepsis and Fanconi's syndrome-like symptoms
while in partial remission (third cycle, dose level 4). The
third patient died of septic shock after refusing to be
transferred to the hospital while febrile.
Moreover, treatment was discontinued in four pa-
tients because of refusal and in two patients because the
maximum dose of doxorubicin was reached. Three pa-
tients went off treatment thanks to complete remission,
and nine because of tumor progression. In 10 patients,
clinical response and stabilization of disease allowed
elective surgery and/or radiotherapy.
Delivered dose intensity
To assess the feasibility of multiple cycles at the maximum
tolerated doses, we studied the median delivered doses
(mg/m2or g/m2) in subsequent cycles at dose levels 2
Location of primary
Soft tissue
Gynecological
Bone
Location of recurrence (one or
more per patient)
Local
Lung metastases
Lymph nodes
Liver metastases
Bone
Histology: soft tissue
Leiomyosarcoma
Synoviosarcoma
Liposarcoma
Neurofibrosarcoma
Other
Histology: gynecologic
Leiomyosarcoma
Mixed mesodermal
Grade
I
II
III
Dose level
Ifo (g/m2) Doxo (mg/m2)
1 12 50
2 12 60
3 10 60
4 10 75
5 10 90
Overall
No.
of
pts
19
10
2
9
14
8
5
4
4
3
3
2
6
6
4
2
10
19
7
4
6
6
8
31
Responses
CR
2
2
0
2
1
3
0
0
-
-
-
_
2
1
1
_
_
4
-
-
1
1
2
4
PR
9
4
0
4
6
1
4
1
3
1
3
-
2
3
1
1
6
6
3
2
2
4
2
13
NC
5
1
1
1
4
0
0
2
-
2
-
2
1
-
1
_
4
3
2
1
3
1
-
7
PD
3
3
1
2
3
4
1
1
1
-
-
-
2
2
1
1
—
6
2
1
_
-
4
7
and 5. At dose level 2, 92% and 97%, respectively, of the
scheduled doses of ifosfamide and doxorubicin could be
administered. At dose level 5, however, the planned dose
of ifosfamide was down by 20% and that of doxorubicin
by 17% (Figure 1). This tendency to reduce ifosfamide
dosage in later cycles by up to 20% had already been
observed at dose level 4, at which time, however, the full
dose of doxorubicin was maintained.
Response and survival
Although anti-tumor response was not the primary
parameter under study, a summary of sarcoma types
and response rates has been compiled in Table 5. The
overall response rate was 55% (95% CI: 36%-73%),
including four complete responders (13%) and 13 (42%)
partial responders. Seven patients (23%) showed stable
disease, and another seven patients (23%) showed pro-
gressive disease. Response was seen not only in soft-
tissue sarcomas but also in six of 10 gynecological sarco-
mas irrespective of histological features.
As mentioned in the methods section, surgery and/or
radiotherapy were proposed to six out of 17 responders,
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hence the effect of these additional procedures is also
reflected in the duration of response. The median follow-
up among survivors was three years. Twelve patients
with remission developed disease progression or died.
The median duration of response was 19 (1.5-48) months,
with 47% (SE 12%) of patients still in remission after
two years. Twenty-three out of the total sample of 33
patients have died by the time of this evaluation. The
median survival was two years, with 25% (SE 8%) of
patients alive after three years. The patients with soft-
tissue sarcomas had survived for a median of 28 months,
with 33% (SE 12%) alive after three years. Causes of
death were for the most part tumor-related. One patient
died of toxicity, and three patients died of causes unre-
lated to tumor or chemotherapy (suicide, n = 1; liver
cirrhosis, n = 1; stroke, n - 1).
Discussion
Only few active agents are available for the treatment of
sarcomas, and their anti-tumor activity - ranging from
17% to 25% - is limited. Developments that add to the
range of active therapeutic strategies have an immediate
clinical impact. Higher response rates will benefit pa-
tients with locally advanced disease in that they enable
higher resection rates. A greater efficacy of active ther-
apeutic regimens may also improve their impact on
micrometastatic disease in the adjuvant setting. Further-
more, raising the complete remission rate among pa-
tients with advanced metastatic disease will potentially
increase the disease-free survival [20].
Combination of active single agents has in some
instances brought the response rate up to 30%-35% [3,
8]. This was not reflected, however, in the survival of
patients with metastatic disease, possibly because of sub-
optimal dosages and a low complete remission rate.
Both doxorubicin and ifosfamide are known to be char-
acterized by a true dose-response relationship, but owing
to the expected hematological toxicity this property has
never been fully exploited in combination regimens.
Hematopoietic growth factors have been shown to en-
hance the tolerance to intensive chemotherapy [21] and
thus enabled us to re-evaluate the option of applying the
maximum tolerated doses in combination.
In the present study we could demonstrate that in
combination with ifosfamide 12 g/m2 the MTD of doxo-
rubicin was 60 mg/m2. Despite GM-CSF this dose level
induced prolonged leukopenia in all analyzed patients,
and one patient additionally showed severe neurotoxic-
ity. However, once ifosfamide was decreased to 10 g/m2
it was possible to further escalate doxorubicin up to 90
mg/m2 while myelosuppression remained within a toler-
able time frame of < 4 days. Only one of eight evaluable
patients developed severe mucositis. Doxorubicin dose
escalation was stopped at that level, which is now being
used in phase II trials. Ifosfamide 10 g/m2 together with
doxorubicin 90 mg/m2 administrated over multiple (to-
tal of 26) cycles induced WHO grade 4 leukopenia in
58% of cycles, with febrile complications requiring anti-
biotics in seven (27%) cases. Severe grade 3-4 thrombo-
penia and anemia occurred in 42% and 31% of cycles,
respectively. Mucositis was minor in half of them. No
neurotoxic events were noticed at that dose level.
Interestingly, there were no major differences in tox-
icity across the tested dose levels by cycles or by patients.
Severe leukopenia and granulopenia were universal.
Febrile episodes, on the other hand, were more frequently
observed after ifosfamide 12 g/m2. Similarly, ifosfamide
at its highest dose level was associated with a deeper
hemoglobin nadir, whereas the maximum dose of doxo-
rubicin led to more severe thrombocytopenia and more
frequently caused mucositis.
However, the toxicity of the studied regimen was not
significantly different from other modes of combination
chemotherapy. Even regimens at standard dose with
doxorubicin 60 mg/m2 and ifosfamide 7.5 g/m2 has led
to substantial grade 3 or higher myelosuppression in
80% of cases, involving a 4% rate of toxic deaths [3]. An
even lower dosage of doxorubicin 50 mg/m2 and ifos-
famide 5 g/m2 induced severe neutropenia in 73% of
patients [22].
The standard combination of doxorubicin 60 mg/m ,
ifosfamide 7.5 g/m2 and dacarbazine 900 mg/m2 (MAID
regimen) led to severe neutropenia in the vast majority of
cases, but its duration was reduced by addition of G-CSF
from up to 10 days in the absence of growth factors to
less than three days [23]. Likewise, the incidence of
febrile episodes was reduced with the help of GM-CSF
from 58% to 23%. Under the protection of GM-CSF,
doxorubicin was increased to 75 mg/m2 in association
with a standard dose of 5 g/m2 ifosfamide [9]. WHO
grade 4 neutropenia was observed in all patients, but its
duration varied between three and six days, and the
neutropenic infection rate was 14%. Doxorubicin ana-
logues like epirubicin have been thought to be less
myelotoxic [24] and to improve the therapeutic index of
combination regimens. Grade 4 leukopenia was indeed
present in 5% of patients after ifosfamide 5 g/m2 and
epirubicin 100 mg/m2 [25]. But when ifosfamide 9 g/m2
was combined with epirubicin escalated from 100 to 140
mg/m2, grade 3-4 leukopenia was observed in 76%-
90%, anemia in 28%-53%, and thrombopenia in 17%-
29% of cycles. Under GM-CSF protection the median
duration of leukopenia was four to five days, with 43%
of patients developing neutropenic fever [26]. Ifosfamide
12.5 g/m2 and epirubicin 90 mg/m2 equally induced
severe myelosuppression in all patients [27]. The use of
hematological stem cells, while failing to reduce the
severity of myelosuppression, allowed further escalation
of ifosfamide to 17.5 g/m2 and of epirubicin to 120 mg/
m2, although nephrotoxicity and hepatotoxicity became
dose-limiting factors [27]. In this way, the anthracycline
analogues had no advantage over doxorubicin in terms
of toxicity [28] and, when given at less myelotoxic doses,
also had less activity [23].
If myelosuppression must be accepted as inherent in
the association of ifosfamide and doxorubicin, the ques-
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tion arises whether this translates into a higher remission
rate. In some studies, myelosuppression was a signifi-
cant prognostic factor for response [29]. Thus, for the
best results, the most active drugs should be given at
doses high enough to eventually induce toxicity [30].
In the study herein reported, the overall response rate
was 55%, including 13% complete responders. Other in-
tensive regimens have yielded similar results, with re-
sponse rates of 45%-69%, including 8%-17% complete
responders [9, 26, 31]. Due to the small sample and
histological heterogeneity of patients at the various dose
levels, we were unable to establish a dose-response
relationship even though the number of complete res-
ponders was greater at the highest dose of doxorubicin.
A similar observation has been made with epirubicin
[26]. The high response rate might be due to good patient
selection. Although response rates have been related by
multivariate analysis to absence of liver metastases,
presence of lung lesions, and young age [32], four of our
five patients with liver metastases showed partial re-
sponse.
Overall, 78% of our patients showed response or
stable disease. Ten of them could be further treated by
surgery and/or radiotherapy in an effort to render them
free of disease. The median survival for the total sample
(33 cases, including early deaths) was 24 months, and
25% of all patients were alive after three years. The
results were even better in the subgroup with soft-tissue
sarcomas, where the three-year survival amounted to
33%. Considering the 12-month median survival after
standard chemotherapy [2], our results confirm the no-
tion that disease-free status and overall survival can be
prolonged by incorporating active chemotherapy in a
multimodality approach [20].
Uterine sarcomas are for the most part resistant to
chemotherapy [33]. Doxorubicin has some activity in
leiomyosarcomas, as have cisplatin and ifosfamide in
mixed mesodermal tumors. Combined ifosfamide 5 g/m2
and doxorubicin 50 mg/m2 was shown to be toxic and
moderately active in metastatic leiomyosarcoma [33].
The response rate in our sample of 10 uterine sarcomas
was 60% irrespective of histological subtypes. Such a
finding is exceptional given the type of disease and needs
to be verified in a larger sample of patients.
To summarize, we were able to demonstrate that the
optimal dose combination of doxorubicin and ifosfa-
mide, administered with hematopoietic growth factors,
was 90 mg/m2 and 10 g/m2 respectively. Myelosuppres-
sion was severe but short and could be managed in a
multicenter setting. Such a degree of myelosuppression
should be regarded as acceptable given the outlook of a
high response rate and an improvement in disease-free
survival. This clinically relevant antitumor activity now
needs to be confirmed in regular phase II trials includ-
ing patients with both gynecological and soft-tissue sar-
comas.
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